BRPI0911490A2 - derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5) - Google Patents

derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5)

Info

Publication number
BRPI0911490A2
BRPI0911490A2 BRPI0911490A BRPI0911490A BRPI0911490A2 BR PI0911490 A2 BRPI0911490 A2 BR PI0911490A2 BR PI0911490 A BRPI0911490 A BR PI0911490A BR PI0911490 A BRPI0911490 A BR PI0911490A BR PI0911490 A2 BRPI0911490 A2 BR PI0911490A2
Authority
BR
Brazil
Prior art keywords
alk4
alk5
kinase inhibitors
receptor kinase
activin receptor
Prior art date
Application number
BRPI0911490A
Other languages
English (en)
Portuguese (pt)
Inventor
Catherine Leblanc
Cathy Ritchie
Duncan Shaw
Nikolaus Johannes Stiefl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0911490A2 publication Critical patent/BRPI0911490A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
BRPI0911490A 2008-04-29 2009-04-27 derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5) BRPI0911490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155405 2008-04-29
PCT/EP2009/055066 WO2009133070A1 (en) 2008-04-29 2009-04-27 Imidazo-pyridine derivatives as activin-like receptor kinase (alk4 or alk5) inhibitors

Publications (1)

Publication Number Publication Date
BRPI0911490A2 true BRPI0911490A2 (pt) 2016-01-05

Family

ID=40043988

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911490A BRPI0911490A2 (pt) 2008-04-29 2009-04-27 derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5)

Country Status (14)

Country Link
US (1) US9079897B2 (cg-RX-API-DMAC7.html)
EP (1) EP2307402B1 (cg-RX-API-DMAC7.html)
JP (1) JP5507543B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100130226A (cg-RX-API-DMAC7.html)
CN (1) CN102015691B (cg-RX-API-DMAC7.html)
AU (1) AU2009242145B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0911490A2 (cg-RX-API-DMAC7.html)
CA (1) CA2722131A1 (cg-RX-API-DMAC7.html)
EA (1) EA201001687A1 (cg-RX-API-DMAC7.html)
ES (1) ES2399175T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010011867A (cg-RX-API-DMAC7.html)
PL (1) PL2307402T3 (cg-RX-API-DMAC7.html)
PT (1) PT2307402E (cg-RX-API-DMAC7.html)
WO (1) WO2009133070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2531500B1 (en) 2010-02-05 2018-01-24 Merck Patent GmbH Hetaryl-[1,8]naphthyridine derivatives
BR112012019561A2 (pt) 2010-02-22 2019-09-24 Merck Patent Gmbh hetarilamino naftiridinas
WO2011146287A1 (en) 2010-05-20 2011-11-24 Takeda Pharmaceutical Company Limited Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
ES2962147T3 (es) 2010-11-08 2024-03-15 Sk Chemicals Co Ltd Resina de ácido poliláctico, procedimiento de preparación de la misma, y película de embalaje que comprende la misma
US20140088174A1 (en) * 2011-04-05 2014-03-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signaling
CN105431148A (zh) 2013-03-07 2016-03-23 加利菲亚生物公司 混合谱系激酶抑制剂及治疗方法
EP3283475B1 (en) * 2015-04-16 2019-10-16 Merck Patent GmbH 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
HK1257171A1 (zh) * 2015-09-23 2019-10-18 Dana Farber Cancer Institute, Inc. 间变性淋巴瘤激酶(alk)和丝氨酸富集蛋白激酶 (sppk)的抑制剂及其使用方法
RU2642456C2 (ru) * 2016-06-29 2018-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный университет им. П.Г. Демидова" Способ получения N-арилзамещенных 3H-имидазо[4,5-b]пиридинов
US11466003B2 (en) 2016-07-29 2022-10-11 Shanghai Yingli Pharmaceutical Co., Ltd Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
CN106831770A (zh) * 2017-03-13 2017-06-13 牡丹江医学院 一种药物组合物及其用于治疗肝硬化的用途
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
WO2020012357A1 (en) * 2018-07-10 2020-01-16 Integral Biosciences Pvt. Ltd. Heterocyclic compounds and methods of use
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
EP4182323B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine amino derivatives as alk5 inhibitors
EP4182322B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
PT4182308T (pt) 2020-07-15 2024-12-04 Chiesi Farm Spa Derivados de piridazinil amino como inibidores de alk5
WO2022136221A1 (en) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CA3232178A1 (en) 2021-09-21 2023-03-30 Daniela PIZZIRANI Pyridazinyl amino derivatives as alk5 inhibitors
US20250270215A1 (en) 2022-04-27 2025-08-28 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
GB9921150D0 (en) * 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
WO2005023246A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
KR101229647B1 (ko) * 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도
CA2657227A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.

Also Published As

Publication number Publication date
CN102015691A (zh) 2011-04-13
PT2307402E (pt) 2013-02-15
CN102015691B (zh) 2014-01-08
KR20100130226A (ko) 2010-12-10
US9079897B2 (en) 2015-07-14
AU2009242145B2 (en) 2012-07-05
CA2722131A1 (en) 2009-11-05
EP2307402A1 (en) 2011-04-13
PL2307402T3 (pl) 2013-05-31
WO2009133070A1 (en) 2009-11-05
MX2010011867A (es) 2010-11-26
EP2307402B1 (en) 2012-11-07
US20110060004A1 (en) 2011-03-10
EA201001687A1 (ru) 2011-06-30
JP5507543B2 (ja) 2014-05-28
ES2399175T3 (es) 2013-03-26
AU2009242145A1 (en) 2009-11-05
JP2011518856A (ja) 2011-06-30

Similar Documents

Publication Publication Date Title
PT2307402E (pt) Derivados de imidazo-piridina como inibidores de cinase semelhante ao recetor de ativina (alk4 ou alk5)
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
ZA201008961B (en) Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
BR112012029405A2 (pt) compostos macrocíclicos como inibidores de trk quinase
ES2598358T8 (es) Derivados de quinolina como inhibidores de PI3K quinasa
BR112013014854A8 (pt) compostos de n-(1h-indazol-4-il)imidazo [1,2-a] piridina-3-carboxamida substituídos como inibidores de tirosina quinase de receptor tipo iii
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
PT2947081T (pt) Imidazois substituídos por 2-piridil como inibidores de alk5 e/ou alk4 terapêuticos
IL218032A0 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
BRPI1005327A2 (pt) derivados de triazolopiridina como inibidores de p38 map quinase
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
CR10849A (es) Derivados de benzamida como agonistas del receptor ep4
EP2498607A4 (en) Kinase Inhibitors
EP2493313A4 (en) Kinase Inhibitors
BRPI0910832A2 (pt) Derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk)
BRPI0910439A2 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk)
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
SI2419427T1 (sl) Biciklični heretociklil derivati kot fgfr kinaze inhibitorji za terapevtsko uporabo
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
EP2558099A4 (en) Kinase inhibitors
BR112012008108A2 (pt) derivados de xantina substituídos
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.